IDeYA darovasertib NDA near completion; pipeline expands via new collaborations
IDEAYA says its darovasertib final NDA submission is imminent after positive FDA feedback, with new data to be presented at ESMO. Pipeline expansion includes a phase III DLL3 ADC trial and new Roche, PRMT5 and CDKN2A collaborations.